Search results for Ifabotuzumab

Ifabotuzumab, Abbexa, abx831357

Ifabotuzumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting EPHA3/REK4, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications.

Ifabotuzumab ELISA Kit, Abbexa, abx395107

Ifabotuzumab ELISA Kit is a quantitative ELISA kit for detection of Ifabotuzumab.Ifabotuzumab (formerly KB004) is a first-in-class therapeutic non-fucosylated IgG1 (human f-allotype) monoclonal antibody being developed by Humanigen (formerly KaloBios Pharmaceuticals) for the treatment of cancer. The drug was licensed from the Ludwig Institute for Cancer Research. The molecule contains a human antibody constant region with V-regions that are 92% identical to human germ-line sequences. Ifabotuzumab targets the ephrin type-A receptor 3 (EphA3) tyrosine kinase. In non-clinical studies, Ifabotuzumab demonstrated potent ex-vivo cell killing of EphA3+ tumor cells obtained from patients with hematologic malignancies.

Ifabotuzumab ELISA Kit, ProteoGenix, KPTX218

Description of Ifabotuzumab ELISA Kit Introduction Ifabotuzumab is a monoclonal antibody that has shown promise as a therapeutic target for various types of cancer. The use of Ifabotuzumab ELISA Kit allows for the detection and measurement of this antibody in biological samples, providing valuable information for researchers and clinicians. In this article, we will explore the structure, activity, and potential applications of Ifabotuzumab ELISA Kit in the field of oncology. Structure of Ifabotuzumab Ifabotuzumab is a fully humanized monoclonal antibody that targets the extracellular domain of the EphA3 receptor. This receptor is overexpressed in various types of cancer cells, making it an attractive therapeutic target. The antibody is composed of two heavy chains and two light chains, each with a specific amino acid sequence. The binding site of Ifabotuzumab is located on the variable region of the heavy chain, allowing for specific and selective targeting of the EphA3 receptor. Activity of Ifabotuzumab The main mechanism of action of Ifabotuzumab is through the inhibition of the EphA3 receptor. This receptor is involved in cell signaling pathways that promote cell growth, survival, and migration. By binding to the receptor, Ifabotuzumab blocks these pathways and prevents cancer cells from proliferating and spreading. Additionally, Ifabotuzumab has been shown to induce antibody-dependent cell-mediated cytotoxicity (ADCC), where immune cells recognize and kill cancer cells that are bound by the antibody. Application of Ifabotuzumab ELISA Kit The Ifabotuzumab ELISA Kit is a valuable tool for researchers and clinicians in the field of oncology. It allows for the detection and measurement of Ifabotuzumab in various biological samples, such as serum, plasma, and tissue extracts. This information can be used to monitor the levels of Ifabotuzumab in patients receiving treatment, as well as to assess the efficacy of the antibody in clinical trials. The ELISA Kit can also be used to screen for potential responders to Ifabotuzumab therapy, as well as to identify patients who may benefit from combination therapy with other targeted agents. Detection of Ifabotuzumab in Biological Samples The Ifabotuzumab ELISA Kit utilizes a sandwich immunoassay format, where the antibody is captured by a specific coating on the plate and then detected by a secondary antibody labeled with an enzyme. The amount of enzyme activity is directly proportional to the amount of Ifabotuzumab present in the sample, allowing for accurate and sensitive measurement. This method is highly specific for Ifabotuzumab and does not cross-react with other antibodies or proteins, ensuring reliable results. Monitoring of Ifabotuzumab Therapy The Ifabotuzumab ELISA Kit can be used to monitor the levels of Ifabotuzumab in patients receiving treatment. This information can help clinicians adjust the dose or frequency of administration to optimize the therapeutic effect. It can also be used to assess the pharmacokinetics of Ifabotuzumab, providing insights into its distribution and elimination from the body. Monitoring the levels of Ifabotuzumab can also help identify patients who may require a higher or lower dose of the antibody to achieve a therapeutic response. Potential for Combination Therapy The Ifabotuzumab ELISA Kit can also be used to identify patients who may benefit from combination therapy with other targeted agents. By measuring the levels of Ifabotuzumab in combination with other antibodies or drugs, researchers can determine the optimal combination and dosing regimen for maximum efficacy. This approach has the potential to improve treatment outcomes and overcome resistance to single-agent therapy. Conclusion

Ifabotuzumab Biosimilar - Research Grade, ichor.bio, ICH5591

Research Grade Ifabotuzumab (HB681016), abinScience, HB681016